AC Immune SA
ACIU
$1.77
-$0.11-5.85%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -92.25% | -- | -- | -- | 1,671,450.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -92.25% | -- | -- | -- | 1,671,450.00% |
| Cost of Revenue | 8.69% | 19.19% | 24.51% | 15.69% | 5.17% |
| Gross Profit | -9,507.78% | 190.56% | -19.52% | -15.69% | 101.13% |
| SG&A Expenses | -0.89% | 10.60% | 22.90% | 28.13% | 11.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 96.03% | 95.21% | 87.16% | 82.35% | 3.28% |
| Total Operating Expenses | 8.60% | 20.27% | 26.24% | 20.88% | 6.63% |
| Operating Income | -430.15% | 147.99% | -22.24% | -20.88% | 79.41% |
| Income Before Tax | -235.76% | 137.12% | -34.43% | -7.96% | 72.50% |
| Income Tax Expenses | 209.09% | -- | -- | -- | -47.62% |
| Earnings from Continuing Operations | -235.75% | 137.11% | -34.41% | -7.94% | 72.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -235.75% | 137.11% | -34.41% | -7.94% | 72.50% |
| EBIT | -430.15% | 147.99% | -22.24% | -20.88% | 79.41% |
| EBITDA | -489.32% | 151.75% | -22.96% | -21.55% | 81.38% |
| EPS Basic | -191.10% | 131.47% | -14.23% | 9.15% | 73.48% |
| Normalized Basic EPS | -191.19% | 131.46% | -14.24% | 9.12% | 73.49% |
| EPS Diluted | -195.95% | 128.36% | -14.23% | 9.15% | 73.48% |
| Normalized Diluted EPS | -191.19% | 131.15% | -14.24% | 9.12% | 73.49% |
| Average Basic Shares Outstanding | 15.27% | 17.85% | 17.65% | 18.85% | 3.75% |
| Average Diluted Shares Outstanding | 15.27% | 19.06% | 17.65% | 18.85% | 3.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
